Human papillomavirus vaccine: Optimism versus prudence;Vacuna contra el virus del papiloma humano: razones para el optimismo y razones para la prudencia

Medicina Clinica

Volumn 131, Issue 7, 2008, Pages 256-263

  Ángel Martínez González, Miguel ^a   Carlos, Silvia ^a   de Irala, Jokin ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B VACCINE; WART VIRUS VACCINE;

ARTICLE; HEPATITIS B; HUMAN; IMMUNOGENICITY; INFECTION RISK; SEXUAL TRANSMISSION; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; VIRUS INFECTION; WART VIRUS; ADOLESCENT; ADULT; FEMALE; FEMALE GENITAL TRACT TUMOR; RISK FACTOR;

ADOLESCENT; ADULT; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RISK FACTORS; YOUNG ADULT;

EID: 58249084522     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1157/13125301     Document Type: Article

References (100)

1. Aslam F., and Qayyum M.A. Catastrophic failures of public health. Lancet 363 (2004) 1553
2. Sturm L.A., Mays R.M., and Zimet G.D. Parental beliefs and decision making about child and adolescent immunization: from polio to sexually transmitted infections. J Dev Behav Pediatr 26 (2005) 441-452
3. Martínez-González M.A., and De Irala J. Medicina preventiva y fracaso clamoroso de la salud pública: llegamos mal porque llegamos tarde. Med Clin (Barc) 124 (2005) 656-660
4. Zimmerman R.K. Ethical analysis of HPV vaccine policy options. Vaccine 24 (2006) 4812-4820
5. Mays R.M., Sturm L.A., and Zimet G.D. Parental perspectives on vaccinating children against sexually transmitted infections. Soc Sci Med 58 (2004) 1405-1413
6. Bosch F.X., Lorincz A., Muñoz N., Meijer C.J., and Shah K.V. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 55 (2002) 244-265
7. Winer R.L., Lee S.K., Hughes J.P., Adam D.E., Kiviat N.B., and Koutsky L.A. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 157 (2003) 218-226
8. Rambout L., Hopkins L., Hutton B., and Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 177 (2007) 469-479
9. Álvarez-Dardet C, Márquez Calderón S, González López-Valcarcel B, Taboada L, Hernández-Aguado I, Porta M. Razones para no decidir con prisas. El País. 6/11/2007.
10. Segura A. Los pros y contras de una vacuna. El País. 11/09/2007.
11. Sociedad Española de Medicina de Familia y Comunitaria. La epidemiología de la infección por VPH y del cáncer de cérvix en España no requiere una intervención sanitaria inmediata [consultado 05/12/2007]. Disponible en: www.semfyc.es
12. Razones para una moratoria en la aplicación de la vacuna del virus del papiloma humano en España. Disponible en: www.caps.pangea.org/declaracion/completa.php
13. Lippman A., Melnychuk R., Shimmin C., and Boscoe M. Human papillomavirus, vaccines and women's health: questions and cautions. CMAJ 177 (2007) 484-487
14. CDC. Quadrivalent human papillomavirus vaccine. Recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep 56 (2007) 1-23
15. Villa L.L. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases. Vaccine 24 Suppl 1 (2006) 23-28
16. The Future II Study Group. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369 (2007) 1861-1868
17. Fusté P., Carreras R., and López-Yarto M.T. Vacunas preventivas frente al virus del papiloma humano y cáncer de cérvix. Med Clin (Barc) 128 (2007) 735-740
18. Brisson M., Van de Velde N., De Wals P., and Boily M.C. Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection. CMAJ 177 (2007) 464-468
19. Gostin L.O., and DeAngelis C.D. Mandatory HPV vaccination: public health vs private wealth. JAMA 297 (2007) 1921-1923
20. Navarro-Alonso J.A., Bernal-González P.J., and Pérez-Martín J.J. Interrogantes en la introducción de la vacuna frente al virus del papiloma humano en los calendarios sistemáticos. Med Clin (Barc) 129 (2007) 55-60
21. Kahn J.A., and Burk R.D. Papillomavirus vaccines in perspective. Lancet 369 (2007) 2135-2137
22. Kulasingam S.L., and Myers E.R. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 290 (2003) 781-789
23. Kulasingam S., Connelly L., Conway E., Hocking J.S., Myers E., Regan D., et al. A cost-effectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health 4 (2007) 165-175
24. Goldie S.J., Kohli M., Grima D., Weinstein M.C., Wright T.C., Bosch F.X., et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 96 (2004) 604-615
25. Van de Velde N., Brisson M., and Boily M.C. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol 165 (2007) 762-775
26. Vilaplana E, Bernaola E, Rodrigo C, Gil A, Vidart JA, De Juanes JR, et al. Vacunas profilácticas frente al VPH. Documento de consenso de las Sociedades Científicas [consultado 05/12/2007]. Disponible en: www.vacunasaep.org
27. Zimet G., Perkins S., Sturm L., Bair R., Juliar B., and Mays R. Predictors of STI vaccine acceptability among parents and their adolescent children. J Adolesc Health 37 (2005) 179-186
28. De Soto J. Should HPV vaccination be mandatory? Should we force drug therapy because patients might get the disease based on future behaviour?. J Fam Pract 56 (2007) 267-268
29. Sawaya G.F., and Smith-McCune K. HPV vaccination - More answers, more questions. N Engl J Med 356 (2007) 1991-1993
30. Velasco J., and Pérez C. Historia natural. In: Alba A., Bosch F.X., Castellsagué X., Junquera M., Muñoz N., Pérez C., et al. (Eds). La infección por VPH (2007), Roche Diagnostics, Barcelona 27-36
31. Raffle A.E. Challenges of implementing human papillomavirus (HPV) vaccination policy. BMJ 335 (2007) 375-377
32. Baden L.R., Curfman G.D., Morrissey S., and Drazen J.M. Human papillomavirus vaccine - opportunity and challenges. N Engl J Med 356 (2007) 1990-1991
33. Hughes J.P., Garnett G.P., and Koutsky L. The theoretical population-level impact of a prophylactic human papillomavirus vaccine. Epidemiology 13 (2002) 631-639
34. Parkin D.M., and Bray F. The burden of HPV-related cancers. Vaccine 24 Suppl 3 (2006) 11-25
35. Trottier H., and Franco E.L. Human papillomavirus and cervical cancer: burden of illness and basis for prevention. Am J Manag Care 17 (2006) S462-S472
36. Wright T.C., Van Damme P., Schmitt H.J., and Meheus A. HPV vaccine introduction in industrialized countries. Vaccine 24 Suppl 3 (2006) 122-131
37. Wright T.C., Bosch F.X., Franco E.L., Cuzick J., Schiller J.T., Garnett G.P., et al. HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts. Vaccine 24 Suppl 3 (2006) 251-261
38. Muñoz N., Castellsagué X., De González A.B., and Gissmann L. HPV in the etiology of human cancer. Vaccine 24 Suppl 3 (2006) 1-10
39. Schiffman M., Castle P.E., Jerónimo J., Rodríguez A.C., and Wacholder S. Human papillomavirus and cervical cancer. Lancet 370 (2007) 890-907
40. Kahn J.A., and Bernstein D.I. Human papillomavirus vaccines and adolescents. Curr Opin Obstet Gynecol 17 (2005) 476-482
41. Stanley M. Immune responses to human papillomavirus. Vaccine 24 Suppl 1 (2006) 16-22
42. Comité Asesor Vacunal de la Asociación Española de Pediatría. Vacuna frente a papilomavirus humano [consultado 05/12/2007]. Disponible en: www.vacunasaep.org
43. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre) Summary report on HPV and cervical cancer statistics in Spain, 2007 [consultado 05/12/2007]. Disponible en: www.who.int
44. Barricarte A., Gil-Setas A., Torroba L., Castilla J., Petit A., Polo I., et al. Enfermedad neumocócica invasiva en la población menor de 5 años de edad de Navarra (2000-2005): impacto de la vacuna conjugada. Med Clin (Barc) 129 (2007) 41-45
45. Barricarte A., Castilla J., Gil-Setas A., Torroba L., Navarro-Alonso J.A., Irisarri F., et al. Effectiveness of the 7-valent pneumococcal conjugate vaccine: a population-based case-control study. Clin Infect Dis 44 (2007) 1436-1441
46. Garnett G.P., and Wadell H.C. Public health paradoxes and the epidemiological impact of an HPV vaccine. J Clin Virol 19 (2000) 101-111
47. Liaw K.L., Hildesheim A., Burk R.D., Gravitt P., Wacholder S., Manos M.M., et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by polymerase chain reaction and its association with acquisition and persistence of other HPVtypes. J Infect Dis 183 (2001) 8-15
48. Sguanci L., Bagnoli F., and Lio P. Modeling HIV quasispecies evolutionary dynamics. BMC Evol Biol 7 Suppl 2 (2007) 5
49. Lipsitch M. Bacterial vaccines and serotype replacement: lessons from Haemophilus influenzae and prospects for Streptococcus pneumoniae. Emerg Infect Dis 5 (1999) 336-345
50. De Villiers E.M., Fauquet C., Broker T.R., Bernard H.U., and Zur Hausen H. Classification of papillomaviruses. Virology 324 (2004) 17-27
51. Muñoz N., Bosch F.X., Castellsagué X., Díaz M., De Sanjosé S., and Hammouda D. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 111 (2004) 278-285
52. Trottier H., and Franco E.L. The epidemiology of genital human papillomavirus infection. Vaccine 24 Suppl 1 (2006) 1-15
53. Muñoz N., Bosch F.X., De Sanjosé S., Herrero R., Castellsagué X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348 (2003) 518-527
54. Pagliusi S.R., Dillner J., Pawlita M., Quint W.G., Wheeler C.M., and Ferguson M. International standard reagents for harmonization of HPV serology and DNA assays-an update. Vaccine 24 Suppl 3 (2006) 193-200
55. Organización Mundial de la Salud. Human papillomavirus and HPV vaccines: technical information for policy-makers and health professionals [consultado 05/12/2007]. Disponible en: www.who.int
56. Cutts F.T., Franceschi S., Goldie S., Castellsagué X., De Sanjosé S., Garnett G., et al. Human papillomavirus and HPV vaccines: a review. Bull World Health Organ 85 (2007) 719-725
57. Knowler W.C., Barrett-Connor E., Fowler S.E., Hamman R.F., Lachin J.M., Walker E.A., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
58. Burchell A.N., Winer R.L., De Sanjosé S., and Franco E.L. Epidemiology and transmission dynamics of genital HPV infection. Vaccine 24 Suppl 3 (2006) 52-61
59. Zimet G.D., Liddon N., Rosenthal S.L., Lazcano-Ponce E., and Allen B. Psychosocial aspects of vaccine acceptability. Vaccine 24 Suppl 3 (2006) 201-209
60. Organización Mundial de la Salud. Global strategy for the prevention and control of sexually transmitted infections: 2006-2015 [consultado 05/12/2007]. Disponible en: www.who.int
61. Anhang R., Goodman A., and Goldie S.J. HPVcommunication: review of existing research and recommendations for patient education. CA Cancer J Clin 54 (2004) 248-259
62. Kuehn B.M. CDC panel backs routine HPV vaccination. JAMA 296 (2006) 640-641
63. Colgrove J. The ethics and politics of compulsory HPV vaccination. N Engl J Med 355 (2006) 2389-2391
64. Pollack A.E., Balkin M., Edouard L., Cutts F., and Broutet N. Ensuring access to HPV vaccines through integrated services: a reproductive health perspective. Bull World Health Organ 85 (2007) 57-63
65. Clifford G.M., Goncalves M.A., and Franceschi S. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS 20 (2006) 2337-2344
66. Lehtinen M., Herrero R., Mayaudd P., Barnabase R., Dillnerg J., Paavonen J., et al. Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine 24 Suppl 3 (2006) 233-241
67. De Irala J., Martínez-González M.A., and Guillén-Grima F. ¿Qué es una variable modificadora del efecto?. Med Clin (Barc) 117 (2001) 297-302
68. Agosti J.M., and Goldie S.J. Introducing HPV vaccine in developing countries -Key challenges and issues. N Engl J Med 356 (2007) 1908
69. Elbasha E.H., Dasbach E.J., and Insinga R.P. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 13 (2007) 28-41
70. Área de Epidemiología Ambiental y Cáncer. Centro Nacional de Epidemiología. Instituto de Salud Carlos III. Mortalidad por cáncer en España. Año 2005 [consultado 05/12/2007]. Disponible en: www.isciii.es
71. Winawer S., Fletcher R., Rex D., Bond J., Burt R., Ferrucci J., et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 124 (2003) 544-560
72. Ladabaum U., and Phillips K.A. Colo-rectal cancer screening differential costs for younger versus older Americans. Am J Prev Med 30 (2006) 378-384
73. Frazier A.L., Colditz G.A., Fuchs C.S., and Kuntz K.M. Cost-effectiveness of screening for colo-rectal cancer in the general population. JAMA 284 (2000) 1954-1961
74. Ladabaum U., and Song K. Projected national impact of colo-rectal cancer screening on clinical and economic outcomes and health services demand. Gastroenterology 129 (2005) 1151-1162
75. Betés M., Muñoz-Navas M.A., Duque J.M., Angós R., Macías E., Súbtil J.C., et al. Use of colonoscopy as a primary screening test for colo-rectal cancer in average risk people. Am J Gastroenterol 98 (2003) 2648-2654
76. th Anniversary: accelerated development of vaccines Bethesda, MD: National Institutes of Health; 2002 [consultado 05/12/2007]. Disponible en: http://www.niaid.nih.gov/dmid/vaccines/jordan20
77. Naucler P., Ryd W., Tornberg S., Strand A., Wadell G., Elfgren K., et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 357 (2007) 1589-1597
78. Mayrand M.H., Duarte-Franco E., Rodrigues I., Walter S.D., Hanley J., Ferenczy A., et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 357 (2007) 1579-1588
79. Adams M., Jasani B., and Fiander A. Human papillomavirus (HPV) prophylactic vaccination: challenges for public health and implications for screening. Vaccine 25 (2007) 3007-3013
80. De Irala J., López del Burgo C., De Fez C.M., Arredondo J., Mikolajczyk R.T., and Stanford J.B. Women's attitudes towards mechanisms of action of family planning methods: survey in primary health centres in Pamplona, Spain. BMC Womens Health 7 (2007) 10
81. Zimet G., Mays R., and Fortenbverry J.D. Vaccines against sexually transmitted infections: promise and problems of the magic bullets for prevention and control. Sex Transm Dis 27 (2000) 49-52
82. Kahn J.A., Zimet G.D., Bernstein D.I., Riedesel J.M., Lan D., Huang B., et al. Pediatricians' intention to administer human papillomavirus vaccine: the role of practice characteristics, knowledge, and attitudes. J Adolesc Health 37 (2005) 502-510
83. Lo B. HPV vaccine and adolescents' sexual activity. BMJ 332 (2006) 1106-1107
84. De Irala J, Hanley M, López C. Propóntelo, propónselo, evitar el sida. Madrid. Ediciones Internacionales Universitarias SA; 2006.
85. Underhill K., Operario D., and Montgomery P. Systematic review of abstinence-plus HIV prevention programs in high-income countries. PLoS Med 4 (2007) e275
86. Moreno Rodríguez MC, Muñoz Tinoco MV, Pérez Moreno PJ, Sánchez Queija I. Los adolescentes españoles y su salud. Resumen del estudio «Health Behaviour in School Aged Children» (HBSC-2002). Madrid: Ministerio de Sanidad y Consumo, Universidad de Sevilla; 2005. Véase también [consultado 07/12/2007]: http://www.hbsc.org/downloads/IntReport04/Part3.pdf
87. Instituto Nacional de Estadística. Interrupciones voluntarias del embarazo. Serie 1992-2005 [consultado 05/12/2007]. Disponible en: www.ine.es
88. Ministerio de Sanidad y Consumo. Interrupción voluntaria del embarazo. Datos definitivos correspondientes al año 2005 [consultado 05/12/2007]. Disponible en: www.msc.es
89. Servicio de Vigilancia Epidemiológica. Centro Nacional de Epidemiología. Instituto de Salud Carlos III. Comentario epidemiológico de las enfermedades de declaración obligatoria y sistema de información microbiológica. España. Bol Epidemiol Sem 14 (2006) 256
90. Blower S.M., and McLean A.R. Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco. Science 265 (1994) 1451-1454
91. ONUSIDA. AIDS epidemic update: December 2007 [consultado 05/12/2007]. Disponible en: www.unaids.org
92. Slomovitz B.M., Sun C.C., Frumovitz M., Soliman P.T., Schmeler K.M., Pearson H.C., et al. Are women ready for the HPV vaccine?. Gynecol Oncol 103 (2006) 151-154
93. Waller J., Marlow L.A., and Wardle J. Mothers' attitudes towards preventing cervical cancer through human papillomavirus vaccination: a qualitative study. Cancer Epidemiol Biomarkers Prev 15 (2006) 1257-1261
94. De Sanjosé S., Almirall R., Lloveras B., Font R., Díaz M., Muñoz N., et al. Cervical human papillomavirus infection in the female population in Barcelona, Spain. Sex Transm Dis 30 (2003) 788-793
95. Clifford G.M., Gallus S., Herrero R., Muñoz N., Snijders P.J., Vaccarella S., et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366 (2005) 991-998
96. Marzo-Castillejo M., Cierco Peguero P., and Del Cura González I. Prevencióndel cáncer de cérvix. Aten Primaria 36 (2005) 328-333
97. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95 (2006) 1459-1466
98. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmerón J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 (2007) 2161-2170
99. Mao C., Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Wiley D.J., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107 (2006) 18-27
100. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al., HPV Vaccine Study group. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255